


















T Gagliano et al. mTOR inhibitors resistance
in bronchial carcinoids
20 :4 463–475mTOR, p70S6K, AKT, and ERK1/2
levels predict sensitivity to mTOR
and PI3K/mTOR inhibitors in human
bronchial carcinoidsTeresa Gagliano1, Mariaenrica Bellio1, Erica Gentilin1,2, Daniela Molè1,
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ztlmch@unife.itAbstractBronchial carcinoids (BCs) are rare neuroendocrine tumors that are still orphans of medical
treatment. Human BC primary cultures may display resistance to everolimus, an inhibitor of the
mammalian target of rapamycin (mTOR), in terms of cell viability reduction. Our aim was to
assess whether the novel dual phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitor NVP-BEZ235
is effective in everolimus-resistant human BC tissues and cell lines. In addition, we searched for
possible markers of the efficacy of mTOR inhibitors that may help in identifying the patients
who may benefit from treatment with mTOR inhibitors, sparing them from ineffective therapy.
We found that NVP-BEZ235 is twice as potent as everolimus in reducing cell viability and
activating apoptosis in human BC tissues that display sensitivity to mTOR inhibitors, but is not
effective in everolimus-resistant BC tissues and cell lines that bypass cyclin D1 downregulation
and escape G0/G1 blockade. Rebound AKT activation was not observed in response to
treatment with either mTOR inhibitor in the ‘resistant’ BC cells. In addition to total mTOR levels,
putative markers of the sensitivity of BCs to mTOR inhibitors are represented by AKT, p70S6K
(RPS6KB2), and ERK1/2 (MAPK3/1) protein levels. Finally, we validated these markers in an
independent BC group. These data indicate that the dual PI3K/mTOR inhibitor NVP-BEZ235 is
more potent than everolimus in reducing the proliferation of human BC cells. ‘Resistant’ cells
display lower levels of mTOR, p70S6K, AKT, and ERK1/2, indicating that these proteins may be
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20 :4 464IntroductionBronchial carcinoids (BCs) are rare neuroendocrine
tumors (NETs) that originate from endocrine cells dis-
persed in the respiratory epithelium and can be divided
into typical BCs (TBCs) and atypical BCs (ABCs) (Cakir &
Grossman 2011). TBCs are, in general, less aggressive,
smaller, and much less likely to metastasize when
compared with ABCs, which are aggressive and may
metastasize to the brain, bone, and liver (Bertino et al.
2009). Currently, the main treatment for BCs is surgery,
which can be curative in most of the cases (Carretta et al.
2000), but is not feasible for large, infiltrating, and
metastatic disease (Gregory et al. 2004). In these settings,
medical therapy is often tried (Fink et al. 2001) and is
mainly represented by chemotherapy and radiation
(Bertino et al. 2009) in the attempt to reduce tumor
mass, while somatostatin analogs are employed for
symptomatic control (Srirajaskanthan et al. 2009).
The mammalian target of rapamycin (mTOR) pathway
plays a central role in the regulation of cell growth,
metabolism, and apoptosis (Jiang & Liu 2008), represent-
ing a novel molecular target for anticancer drugs (Guertin
& Sabatini 2005). mTOR associates with two sets of
different proteins, forming either the mTORC1 complex
or the mTORC2 complex, with the former being more
sensitive to rapamycin than the latter (Loewith et al.
2002). It has been demonstrated that the mTOR pathway
is constitutively activated in NETs (Capdevila et al. 2011),
providing the basis for the development of specific mTOR
inhibitors as new therapeutic tools for NETs (Dong et al.
2012), including BCs (Dong & Yao 2011). Despite their
potential efficacy as anticancer agents, mTOR inhibitors
have demonstrated erratic clinical activity (Wang & Sun
2009), indicating the need to identify possible efficacy
markers. Recently, a differential mTOR activation status
has been demonstrated in the spectrum of bronchopul-
monary NETs, possibly suggesting that profiling of the
mTOR pathway might predict patients’ responsiveness to
mTOR-targeted therapies (Righi et al. 2010). In keeping
with this finding, we have recently demonstrated that
w70% of human BC primary cultures respond to a mTOR
inhibitor, everolimus, in terms of cell viability reduction.
In these settings, the efficacy of everolimus correlated with
mTOR expression, tumor size, mitotic index, angiogenic
markers, and plasma chromogranin A levels (Zatelli et al.
2010a,b). In other settings, resistance to everolimus has
been attributed to rebound AKT activation by the
mTORC2 complex. It has indeed been demonstrated that
AKT phosphorylation is increased in cancer biopsies ofhttp://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-13-0042 Printed in Great Britainpatients treated with everolimus when compared with the
controls (O’Reilly et al. 2006). However, the mechanisms
underlying the resistance of BCs to everolimus have not
been clarified, so far.
The relative lack of sensitivity to currently employed
mTOR inhibitors may be bypassed by using multi-
target agents, such as NVP-BEZ235. The latter is an
imidazo (4,5-c)quinoline derivative that inhibits both
phosphatidylinositol 3-kinase (PI3K) and mTOR acti-
vities, inducing G1 arrest in cell-cycle progression (Maira
et al. 2008). It has been demonstrated previously that
NVP-BEZ235 dose dependently reduces cell viability and
promotes apoptosis in a human TBC cell line, the
NCI-H727 cells, as well as in other human NET cell
lines, with a greater potency than everolimus (Zitzmann
et al. 2010). However, there is no evidence, so far, that
NVP-BEZ235 may be effective in BCs not responding to
everolimus. In addition, the markers of efficacy of both
drugs are yet to be identified.
Therefore, the aim of our study was to assess whether
the novel dual PI3K/mTOR inhibitor is effective in
everolimus-resistant human BC tissues and cell lines. In
addition, we searched for possible markers of the efficacy
of mTOR inhibitors that may help in identifying the
patients who may benefit from treatment with mTOR
inhibitors, sparing them from ineffective therapy.Materials and methods
Human BC tissue collection and primary culture
Samples were derived from 21 patients diagnosed with
BCs, whose characteristics are given in Table 1, who were
operated on at the University of Ferrara (Section of
Endocrinology, Institute of Surgery) and at the University
of Padova (Department of Medical and Surgical Sciences).
All patients (12 males and 9 females; ageZ52G4.3 years;
medianZ53 years) underwent BC resection, and all but
two had histological and immunohistochemical diagnosis
of TBCs, according to the WHO classification (Travis &
Brambilla 2004; Table 1).
Tissues were collected following the guidelines of the
local committee on human research and immediately
minced in RPMI-1640 medium under sterile conditions.
Primary cultures were prepared as described previously
(Zatelli et al. 2005, 2010a,b). Experiments were performed
within 3 days in order to prevent the decrease in cell
viability due to culture conditions and to avoid fibroblastPublished by Bioscientifica Ltd.
Downloaded from Bioscientifica.com at 12/10/2020 09:27:46AM
via free access
Table 1 Clinical characteristics of BC patients.
Patient no. Sex Age Side Diameter (cm) Histology TNM
1 M 38 dx 1.7 Typical carcinoid T1a N0 Mx
2 F 61 dx 2 Typical carcinoid T1a N0 Mx
3 M 46 dx 2 Typical carcinoid T1a N0 Mx
4 M 75 sx 1.5 Typical carcinoid T1a N0 Mx
5 M 18 dx 2 Typical carcinoid T1a N0 Mx
6 F 65 dx 2 Typical carcinoid T1a N0 Mx
7 M 68 dx 1.7 Typical carcinoid T1a N0 Mx
8 F 21 dx 1.4 Typical carcinoid T1a N0 Mx
9 F 53 dx 3 Typical carcinoid T1a N0 Mx
10 F 20 dx 2.8 Typical carcinoid T1b N1 Mx
11 M 52 dx 1.8 Atypical carcinoid T4 N3 M1b
12 M 32 sx 1.3 Typical carcinoid T1a N0 Mx
13 M 70 sx 2 Typical carcinoid T1a N2 Mx
14 F 76 sx 0.7 Typical carcinoid T1a N0 Mx
15 F 42 sx 3.5 Typical carcinoid T2a N0 Mx
16 M 69 dx 3.5 Typical carcinoid T2a N1 Mx
17 M 70 dx 2.5 Typical carcinoid T1b N2 Mx
18 F 47 dx 1.8 Typical carcinoid T1a N0 Mx
19 F 35 dx 4.5 Typical carcinoid T3 N0 Mx
20 M 58 sn 1 Typical carcinoid T1a N0 Mx
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20 :4 465overgrowth, which is observed after 4 days of culture.
Informed consent of the patients was obtained for
disclosing clinical investigation and performing the
in vitro study.Cell line culture
NCI-H727, derived from a TBC, and NCI-H720, derived
from an ABC, cell lines were purchased from American
Type Culture Collection (ATCC, Manassas, VA, USA) and
were grown in RPMI-1640 medium (Euroclone, Milano,
Italy), supplemented with 10% fetal bovine serum, at
37 8C in a humidified atmosphere with 5% CO2.Compounds
Everolimus and NVP-BEZ235 were provided by Novartis.
All other reagents, if not otherwise specified, were
purchased from Sigma.
Viable cell number assessment
Variations in viable cell number were assessed using the
ATPlite kit (Perkin Elmer Life Sciences, Boston, MA, USA),
seeding 2!104 cells/well in 96-well white plates, as
described previously (Molè et al. 2011), and treated with
the indicated compounds for 72 h. Control cells were
treated with the vehicle alone (0.1% DMSO). After
incubation, the revealing solution was added, and the
luminescent output (relative luminescence units (RLU))http://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-13-0042 Printed in Great Britainwas recorded using the Envision Multilable Reader (Perkin
Elmer, Monza, Italy). The results are expressed as mean
valueGS.E.M. percent RLU vs the vehicle-treated control
cells from three independent experiments in six replicates.Caspase activity
Caspase activity was measured using the Caspase-Glo 3/7
assay (Promega) as described previously (Zatelli et al.
2010a,b). Briefly, 2!104 cells/well were seeded in 96-well,
white-walled plates and treated with the indicated
compounds for 72 h. Then, the Caspase-Glo 3/7 reagent
was added at room temperature directly to the cell culture
plates, which were shaken at 12.7 g for 30 s, incubated for
1 h, and then measured for luminescent output (relative
luminescence unit (RLU)) using the Envision Multilabel
Reader (Perkin Elmer). The results are expressed as mean
valueGS.E.M. percent RLU vs the vehicle-treated control
cells from three independent experiments in six replicates.Flow cytometry
Cell-cycle analysis was performed using the CyFlow space
cytometer (Partec, Münster, Germany). The NCI-H727 and
NCI-H720 cells were treated with 100 nM everolimus or
NVP-BEZ235 for 72 h. Vehicle-treated cells served as the
controls. At the end of the incubation period, the cells
were washed with PBS and incubated with 1 ml of
staining solution (5 mg/ml propidium iodide, 10 mg/mlPublished by Bioscientifica Ltd.
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20 :4 466ribonuclease A, 0.1% sodium citrate, and 0.1% Triton
X-100) overnight. A total of 2!104 events were acquired
and analyzed using the FloMax Software (Partec), as
described previously (Minoia et al. 2012).RNA extraction and quantitative PCR
Total RNA was extracted from the cell lines using the
TRIzol reagent following the manufacturer’s instructions
(Invitrogen). RNA integrity was evaluated using the
Experion automated electrophoresis system (Bio-Rad
Laboratories). Only RNA samples with a 28S:18S rRNA
ratio O1.6 and an RNA quality indicator O9 were
processed. All RNA samples were subjected to DNase I
treatment. The RNA samples were subjected to RT with
random hexamers, as described previously (Zatelli et al.
2002). Real-time quantitative PCR (Q-PCR) was performed
to assess the expression of human mTOR (Hs.338207)
using the TaqMan gene expression assay (Applied Biosys-
tems). The samples were run in triplicate on an Applied
Biosystems 7700 ABI Prism thermal cycler and analyzed
with the SDS 1.9 Software (Applied Biosystems), by
applying the method described by Pfaffl (2001).
To ensure the fidelity of mRNA extraction and RT,
human target gene signals from all samples were normalized
against five different housekeeping genes: 18S rRNA,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
b-actin (ACTB), human PO (ribosomal protein large), and
human GUS (GUSB) (glucuronidase, b). All primers and
probes were commercially available (Applied Biosystems).
Calculations to estimate the expression stability and the
pairwise variation were performed with the freely available
GeNorm program. Data were normalized on human PO
as described previously (Tagliati et al. 2010).Western blot analysis
Frozen human BC tissues were disrupted using Tissue-
Raptor (Qiagen) according to the manufacturer’s instruc-
tions. For immunoblotting, human BC cell lines and
disrupted tissues were dissolved in RIPA buffer (Pierce,
Rockford, IL, USA), kept in ice for 30 min, and then
centrifuged for 10 min. The supernatant, containing the
proteins, was then transferred to a new tube and protein
concentration was measured using the BCA Protein Assay
Reagent Kit (Pierce), as described previously (Tagliati et al.
2006). For protein evaluation, lysates were fractionated on
10% SDS–PAGE, as described previously (Tagliati et al.
2006), and transferred by electrophoresis to nitrocellulose
transfer membranes (PROTRAN, Dassel, Germany). Thehttp://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-13-0042 Printed in Great Britainmembranes were incubated with the following antibodies:
polyclonal rabbit anti-human b-actin (Cell Signaling,
Beverly, MA, USA), polyclonal rabbit anti-mTOR (Santa
Cruz Biotechnology), polyclonal rabbit anti-phosho
(Ser2448) mTOR (Abcam, Cambridge, UK), polyclonal
rabbit anti-human AKT (Cell Signaling), polyclonal rabbit
anti-human phosho (Ser473) AKT (Cell Signaling), poly-
clonal rabbit anti-human glycogen synthase kinase 3b
(GSK3b) and anti-phospho (Ser9) GSK3b (Cell Signaling),
polyclonal rabbit anti-human ERK1/2 and phospho
(Thr202/Tyr204) ERK1/2 (Cell Signaling), and monoclonal
mouse anti-human p70S6K and phospho (Thr389) p70S6K
(Cell Signaling). All the antibodies were diluted at 1:1000.
Anti-rabbit or anti-mouse HRP-conjugated IgG antibodies
(Dako Italia, Milano, Italy) were used at a dilution of
1:5000, and binding was revealed using ECL (Pierce). The
blots were then stripped and used for further blotting.
Quantification of band intensity was done using a Gel
Doc System with the Quantity One Software (Bio-Rad).Kinase activity assay
Total and phosphorylated p70S6K (RPS6KB2) levels and
total and phosphorylated ERK1/2 (MAPK3/1) levels were
measured using the AlphaScreen SureFire total p70S6K
assay, p-p70S6K (Thr389) assay, total ERK1/2 assay, and
p-ERK1/2 (Thr202/Tyr204) assay (Perkin Elmer). Briefly,
the cells were seeded at 2!104 cells/well in 96-well plates
and, after overnight attachment, were incubated with or
without everolimus or NVP-BEZ235 and evaluated as per
the manufacturer’s protocol. The plates were measured in
Read plate on an Envison plate reader (Perkin Elmer),
using standard AlphaScreen settings, and the output was
recorded as counts per second (cps).Statistical analysis
Concerning the results of cell viability and caspase 3/7
activation experiments, a preliminary analysis was carried
out to determine whether the datasets conformed to a
normal distribution, and a computation of homogeneity
of variance was performed using Bartlett’s test. The results
were compared within each group and between the groups
using ANOVA. If the F values were significant (P!0.05),
Student’s paired or unpaired t-test was used to evaluate
individual differences between the means. P values !0.05
were considered significant. For all the other experiments,
Student’s paired or unpaired t-test was used to evaluate
individual differences between the means, and P values
!0.05 were considered significant.Published by Bioscientifica Ltd.
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Effects of NVP-BEZ235 and everolimus on BC primary
cultures
We evaluated the ability of NVP-BEZ235 and everolimus to
influence cell viability in 21 dispersed human BC primary
cultures, which were divided into primary cultures
displaying a significant reduction (P!0.05) in cell viability
under everolimus treatment, referred to as ‘sensitive’, and
those that did not, referred to as ‘resistant’. Table 2 reports
cell viability reduction observed under NVP-BEZ235 or
everolimus treatment when compared with the control
in each BC primary culture. According to this criterion,
cultures from 13 BCs were considered as ‘sensitive’ and
those from 8 BCs as ‘resistant’. All BC primary cultures
that were considered as ‘sensitive’ to everolimus also
displayed a significant reduction (P!0.05) in cell viability
under treatment with NVP-BEZ235. As shown in Fig. 1A,
in the ‘sensitive’ group (black bars), both NVP-BEZ235
and everolimus significantly (P!0.01) reduced cell
viability (K32.3 and K18.4% respectively). Furthermore,
in the ‘sensitive’ group, NVP-BEZ235 was 1.8-fold more
potent than everolimus in terms of cell viability reductionTable 2 Percent cell viability reduction under NVP-BEZ235 or
everolimus treatment.
Patient no. NVP-BEZ235 R/S Everolimus R/S
1 K33 S K26 S
2 13 R 1 R
3 K20 S K10 S
4 K2 R 10 R
5 K41 S K27 S
6 K19 S K12 S
7 K7 R K5 R
8 K18 S K12 S
9 K58 S K50 S
10 K39 S K20 S
11 K31 S K12 S
12 K37 S K11 S
13 1 R 1 R
14 K3 R K3 R
15 3 R 1 R
16 K35 S K16 S
17 K2 R K1 R
18 K34 S K15 S
19 K29 S K13 S
20 K26 S K15 S
21 K2 R K1 R
Human BC primary cultures were each incubated with 100 nM NVP-BEZ235
or everolimus, and control cells were treated with a vehicle solution; cell
viability was measured, and it is expressed as the mean percent cell viability
reduction vs the untreated control cells. Human BC primary cultures were
divided into cultures displaying a significant reduction (P!0.05) in cell
viability under everolimus treatment, referred to as ‘sensitive’ (S), and
those that did not, referred to as ‘resistant’ (R).
http://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-13-0042 Printed in Great Britain(P!0.01). In the ‘resistant’ BCs (white bars), both
NVP-BEZ235 and everolimus did not significantly modify
the viability of BC cells.
In order to verify whether the reduction in cell viability
caused by NVP-BEZ235 and everolimus was due to the
induction of apoptotic mechanisms, caspase 3/7 activation
was evaluated. As shown in Fig. 1B, in the ‘sensitive’ group
(black bars), both NVP-BEZ235 and everolimus signi-
ficantly (P!0.01) induced caspase activation (C43.6 and
C29.6% respectively); NVP-BEZ235 was 1.5-fold more
potent than everolimus. In the ‘resistant’ BCs (white
bars), both NVP-BEZ235 and everolimus did not signi-
ficantly modify the caspase 3/7 activity of BCs.
Western blot analysis showed that both the total and
phosphorylated forms of the mTOR protein were higher in
the ‘sensitive’ group than in the ‘resistant’ group (Fig. 1C).
Regarding the patients’ characteristics (Table 1), no
difference was found between patients with ‘sensitive’
vs ‘resistant’ BCs concerning gender, tumor site, TNM,
staging, and tumor size. However, patients whose BCs
were ‘sensitive’ to mTOR inhibitors were significantly
(P!0.01) younger than patients whose BCs were ‘resistant
(42.6G3.8 vs 67.3G2.5 years).mTOR expression in human BC cell lines
Both the NCI-H727 and NCI-H720 cell lines were charac-
terized for mTOR expression. As shown in Fig. 2A, mTOR
expression levels in terms of mRNA were 1.5-fold higher
(P!0.05) in the NCI-H720 cells than in the NCI-H727 cells.
These data were confirmed by western blot analysis
(Fig. 2B): the NCI-H720 cells exhibited higher levels of
mTOR protein (both total and phosphorylated forms) than
the NCI-H727 cells. In terms of mTOR expression, the
NCI-H720 and NCI-H727 cells resembled the ‘sensitive’
BC group and the ‘resistant’ BC group respectively.Influence of NVP-BEZ235 and everolimus on cell viability,
apoptosis, and cell-cycle progression in human BC
cell lines
As shown in Fig. 3A, the viability of the NCI-H720 cells
was significantly reduced by treatment with 50 nM–1 mM
NVP-BEZ235 by 55–69% (P!0.01 vs the control;
IC50Z0.32 mM) and by treatment with 50 nM–1 mM ever-
olimus by 31–54% (P!0.01 vs the control; IC50Z0.7 mM).
Therefore, NVP-BEZ235 showed a twofold potency when
compared with everolimus in reducing the viability of the
NCI-H720 cells (Fig. 3A, upper panel). Caspase activation
in the NCI-H720 cells was significantly induced byPublished by Bioscientifica Ltd.
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20 :4 468treatment with 50 nM–1 mM NVP-BEZ235 by 160–290%
(P!0.01 vs the control; IC50Z0.073 mM) and by treatment
with 250 nM–1 mM everolimus by 13–44% (P!0.01 vs the
control; IC50Z0.69 mM). Thus, NVP-BEZ235 showed a
tenfold potency when compared with everolimus in
inducing caspase activation in the NCI-H720 cells
(Fig. 3A, lower panel).
As shown in Fig. 3B, the viability of the NCI-H727
cells was significantly reduced by treatment with
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DOI: 10.1530/ERC-13-0042 Printed in Great Britaincontrol; IC50Z0.99 mM) and by treatment with 50 nM–
1 mM everolimus by 10–42% (P!0.01 vs the control;
IC50Z1.07 mM). Therefore, NVP-BEZ235 showed a potency
that was similar to that shown by everolimus in reducing
the viability of the NCI-H727 cells (Fig. 3B, upper panel).
Caspase activation in the NCI-H727 cells was significantly
induced by treatment with 500 nM–1 mM NVP-BEZ235
by 20% (P!0.01 vs the control; IC50Z1.65 mM) and
by treatment with 500 nM–1 mM everolimus by 10–15%
(P!0.01 vs the control; IC50Z3.14 mM). Therefore,
NVP-BEZ235 showed a twofold potency when compared
with everolimus in inducing caspase activation in the
NCI-H727 cells (Fig. 3B, lower panel).
These data show that the NCI-H720 cells are more
sensitive than the NCI-H727 cells to the antiproliferative
effects of both the employed drugs. In addition, the reduction
in cell viability induced by treatment with either NVP-
BEZ235 or everolimus was not completely mirrored by
apoptosis activation. Therefore, the influence of NVP-
BEZ235andeverolimusoncell-cycleprogressionwasverified.
As shown in Fig. 4A, in the NCI-H720 cells, treatment
with 100 nM NVP-BEZ235 caused a 11.5% increase
(P!0.05 vs the control) in the number of cells in the
G0/G1 phase of the cell cycle, with 7 and 4.5% reductions
(P!0.05) in the number of cells in the S and G2/M phases
respectively. Similarly, treatment with 100 nM everolimus
caused an 8.7% increase (P!0.05) in the number of cells in
the G0/G1 phase of the cell cycle, with 5.2 and 3.4%
reductions (P!0.05) in the number of cells in the S and
G2/M phases respectively.
As shown in Fig. 4B, in the NCI-H727 cell line,
treatment with 100 nM NVP-BEZ235 caused a 4.7%
increase in the number of cells in the G0/G1 phase ofFigure 1
Effects of mTOR inhibitors and mTOR expression in human BC primary
cultures. BC cells were incubated in 96-well plates for 72 h in a culture
medium supplemented with 100 nM NVP-BEZ 235 or everolimus, and
control cells were treated with a vehicle solution. (A) Cell viability of each
primary culture was measured as a luminescent output. As described in the
Results section, the samples were divided according to cell viability
inhibition after treatment with everolimus into ‘sensitive’ (13 samples,
black bars) and ‘resistant’ (eight samples, white bars) groups. Data from BC
primary cultures were evaluated independently with six replicates each,
and they are expressed as the meanGS.E.M. percent cell viability inhibition
vs the untreated control cells. **P!0.01 vs the untreated control cells.
(B) Caspase activity was measured as a luminescent output in the ‘sensitive’
(black bars) and ‘resistant’ (white bars) primary cultures. Data from BC
primary cultures were evaluated independently with six replicates each,
and they are expressed as the meanGS.E.M. percent caspase activity vs the
untreated control cells. **P!0.01 vs the untreated control cells. (C) Western
blot analysis for total mTOR and phosphorylated mTOR (p-mTOR) expression
in a pool of ‘sensitive’ (S) human BC tissues and in a pool of ‘resistant’ (R)
human BC tissues. b-Actin is shown as a loading control.
Published by Bioscientifica Ltd.







































mTOR expression in human BC cell lines. (A) Total RNA was isolated from
the NCI-H727 and NCI-H720 cells and relative Q-PCR for mTOR expression
was performed. The experiment was repeated thrice, and the results are
expressed as a fold of induction of mTOR expression levels compared with
the NCI-H727 cells, considered as the reference. (B) Total proteins were
isolated from the NCI-H727 and NCI-H720 cells and western blot analysis for
total mTOR and phosphorylated mTOR (p-mTOR) protein expression was
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20 :4 469the cell cycle, with 6.9 and 2.1% reductions in the number
of cells in the S and G2/M phases respectively. Similarly,
treatment with 100 nM everolimus caused a 4.7% increase
in the number of cells in the G0/G1 phase of the cell cycle,
with 6.9 and 2.1% reductions in the number of cells in
the S and G2/M phases respectively. All the variations in
cell-cycle distribution recorded in the NCI-H727 cells did
not reach statistical significance.
These data show that both NVP-BEZ235 and ever-
olimus influence cell-cycle progression by inducing a delay
in the G1 phase only in the NCI-H720 cells. Since the
transition from the G1 to the S phase is also regulated by
cyclin D1 expression levels, the latter were assessed in
the NCI-H720 and NCI-H727 cells treated with 100 nM
NVP-BEZ235 or everolimus (Fig. 4C). Western blot analysishttp://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-13-0042 Printed in Great Britainshowed that treatment with NVP-BEZ235 caused a sharp
reduction in cyclin D1 protein levels in both the NCI-H720
and NCI-H727 cells, while everolimus reduced cyclin D1
protein levels in both the NCI-H720 and NCI-H727 cells
to a smaller extent. It has been demonstrated previously
that GSK3b activation promotes cyclin D1 degradation
(Kunnimalaiyaan et al. 2007). Figure 4C shows that both
NVP-BEZ235 and everolimus are capable of reducing
the phosphorylation levels of GSK3b at Ser 9 in both the
NCI-H720 and NCI-H727 cells, indicating an increase in
kinase activity of the enzyme (Martin et al. 2005).PI3K/AKT/mTOR pathway expression and activation
in BC cell lines
In order to understand whether the sensitivity to mTOR
inhibitors is related to the expression levels of mTOR
pathway components, protein expression was evaluated
by western blot analysis. As shown in Fig. 5A, in keeping
with the results shown in Fig. 2, total and phosphorylated
mTOR basal levels were higher in the NCI-H720 cells than
in the NCI-H727 cells. In addition, phosphorylated mTOR
levels were reduced by both 100 nM NVP-BEZ235 and
everolimus, with the latter being more potent, in both the
NCI-H720 and NCI-H727 cells. On the other hand, total
mTOR protein levels were not significantly influenced by
treatment with either mTOR inhibitor.
Similarly, both total and phosphorylated basal AKT
protein levels were higher in the NCI-H720 cells than in
the NCI-H727 cells; basal AKT levels were not influenced
by treatment with mTOR inhibitors. On the other hand,
phosphorylated AKT protein levels were slightly reduced
by treatment with NVP-BEZ235 but not by treatment with
everolimus in the NCI-H720 cells. In the NCI-H727 cells,
phosphorylated AKT levels were not affected by treatment
with either mTOR inhibitor (Fig. 5A). One of the main
downstream mTOR targets is represented by p70S6K,
a serine/threonine kinase, the phosphorylation of which
induces protein synthesis at the ribosome (Loewith et al.
2002). Therefore, we investigated p70S6K phosphoryl-
ation and found this parameter to be significantly reduced
by both NVP-BEZ235 and everolimus by 55–60% (P!0.01)
in the NCI-H720 cells but not in the NCI-H727 cells
(Fig. 5B). In addition, basal total p70 levels were twofold
higher in the NCI-H720 cells than in the NCI-H727 cells
(data not shown), as evident for the phosphorylated basal
p70 levels (Fig. 5B).
The ERK1/2 pathway actively participates in the
signals inducing cell proliferation also by promoting
cyclin D1 transcription (Kumar et al. 2013). Moreover,Published by Bioscientifica Ltd.























































































































































Effects of mTOR inhibitors on cell viability and caspase activation in human
BC cell lines. (A) The NCI-H720 cells were incubated in 96-well plates for
72 h in a culture medium supplemented with 100 nM NVP-BEZ 235 (black
bars) or everolimus (white bars), and control cells were treated with a
vehicle solution. Upper panel: cell viability was measured as a luminescent
output in three independent experiments with six replicates each, and it is
expressed as the meanGS.E.M. percent cell viability inhibition vs the
untreated control cells. **P!0.01 vs the untreated control cells. IC50 (mM)
for cell viability reduction is reported in Table 2. Lower panel: caspase
activity was measured as a luminescent output in three independent
experiments with six replicates each, and it is expressed as the meanGS.E.M.
percent caspase activity vs the untreated control cells. **P!0.01 vs the
untreated control cells. IC50 (mM) for caspase 3/7 activity induction is
reported in Table 2. (B) The NCI-H727 cells were incubated in 96-well plates
for 72 h in a culture medium supplemented with 100 nM NVP-BEZ 235
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independent of mTOR and AKT activation. Therefore, we
investigated ERK1/2 phosphorylation and found this
parameter to be significantly reduced by both NVP-BEZ235
and everolimus in the NCI-H720 cells by 20–60% (P!0.01),
but not in the NCI-H727 cells (Fig. 5C). In addition, basal
total ERK1/2 levels were 25-fold higher in the NCI-H720
cells than in the NCI-H727 cells (data not shown), as evident
for phosphorylated ERK1/2 basal levels (Fig. 5C).mTOR, p70S6K, AKT, and ERK1/2 levels in independent
human BC tissues
In order to validate the putative markers identified
in the two human BC cell lines, we evaluated a grouphttp://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-13-0042 Printed in Great Britainof independent human BC tissues, already described
in a previously published study as either ‘sensitive’ or
‘resistant’ to everolimus (Zatelli et al. 2010a,b). We
randomly selected five ‘sensitive’ and five ‘resistant’
human BC tissues and analyzed the expression of total
and phosphorylated mTOR, p70S6K, AKT, and ERK1/2
protein levels by western blot analysis. As shown in
Fig. 5D, we found that both total and phosphorylated
mTOR and AKT protein levels were w20-fold higher in
the ‘sensitive’ BCs than in the ‘resistant’ BCs. Similarly,
both total and phosphorylated p70S6K levels were
approximately sixfold higher in the ‘sensitive’ BCs than
in the ‘resistant’ BCs. Total and phosphorylated ERK1/2
protein levels were five- and twofold higher in the
‘sensitive’ BCs than in the ‘resistant’ BCs respectively.Published by Bioscientifica Ltd.
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Effects of mTOR inhibitors on cell-cycle progression, GSK3b, and cyclin
D1 expression in human BC cell lines. The NCI-H720 and NCI-H727 cells
were incubated for 72 h in a culture medium supplemented with
100 nM NVP-BEZ 235 or everolimus, and control cells were treated with
a vehicle solution. Cell cycle was analyzed in three independent
experiments in the NCI-H720 (A) and NCI-H727 (B) cells. *P!0.05 vs the
untreated control cells. (C) Total proteins were isolated from the
NCI-H727 and NCI-H720 cells and western blot analysis for total GSK3b,
phosphorylated GSK3b (p-GSK3b), and cyclin D1 (cyclin D1) protein
expression was performed. b-Actin is shown as a loading control.
Lane 1, mock-treated cells. Lane 2, cells treated with NVP-BEZ235.
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DOI: 10.1530/ERC-13-0042 Printed in Great BritainDiscussion
In this study, we confirmed that, in keeping with
previously published evidence (Zatelli et al. 2010a,b),
62% of human BC primary cultures respond to treatment
with everolimus with a significant reduction in cell
viability paralleled by apoptosis activation. We also
showed for the first time that the novel PI3K/mTOR
inhibitor NVP-BEZ235 is twice as potent as everolimus in
inhibiting the viability of BC primary culture cells,
indicating that the PI3K pathway plays an important
role in the regulation of the proliferation of BC cells. This
hypothesis is further supported by the evidence that
mTOR inhibitor-sensitive BC tissues display higher levels
of p70S6K, AKT, and ERK1/2 than the resistant BC tissues.
In addition, we found that human BC tissues that are
resistant to everolimus are not responsive to NVP-BEZ235
either, suggesting that pathways different from the PI3K
pathway should be inhibited to overcome the resistance
to mTOR inhibitors in BCs.
In agreement with our previous results (Zatelli et al.
2010a,b), ‘sensitive’ BC tissues showed higher levels of
total and phosphorylated mTOR than the ‘resistant’ BCs,
supporting the hypothesis that mTOR expression levels
may be useful to separate ‘sensitive’ tumors from ‘resistant’
tumors (Rossi et al. 2012). It has been hypothesized
previously that resistance to everolimus may be overcome
by the use of drugs inhibiting PI3K/AKT (Bousquet et al.
2012). Indeed, everolimus inhibits mTOR by interacting
with the mTORC1 complex, which, in turn, inhibits
p70S6K phosphorylation. The latter normally exerts a
negative feedback on the PI3K/AKT/mTOR pathway
activated by growth factors. Therefore, treatment with
everolimus may cause rebound activation of the PI3K/AKT
pathway by reducing p70S6K phosphorylation (Haruta
et al. 2000, Shi et al. 2005, Sun et al. 2005). However, in our
experimental settings, NVP-BEZ235, which inhibits both
PI3K and mTOR, did not overcome the resistance of BCs to
mTOR inhibitors. Therefore, it is crucial to identify
possible markers that may predict tumor sensitivity to
mTOR inhibitors in order to employ mTOR inhibitor
therapy only in those patients who are likely to respond.
We employed two human BC cell lines, the NCI-H720 and
the NCI-H727 cells, displaying different levels of total and
phosphorylated mTOR protein. Indeed, our data show that
the NCI-H720 cells display higher total and phosphory-
lated mTOR protein levels than the NCI-H727 cells, similar
to what has been observed in the ‘sensitive’ and ‘resistant’
BCs respectively. These human cell lines can be considered
a reliable model, since the NCI-H720 cells, which havePublished by Bioscientifica Ltd.
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olimus in terms of cell viability reduction and apoptosis
activation than the NCI-H727 cells, which exhibit lower
mTOR levels. In addition, our data show that in the
‘sensitive’ group of human BC primary cultures, NVP-
BEZ235 is two- to threefold more effective in terms of cell
viability reduction and apoptosis activation than ever-
olimus. Similarly, in ‘sensitive’ NCI-H720 cells, NVP-
BEZ235 is twice as potent as everolimus. On the other
hand, the efficacy of NVP-BEZ235 is very much reduced in














































































































http://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-13-0042 Printed in Great Britainreduction is very similar for NVP-BEZ235 and everolimus
in the NCI-H727 cells, as has been also reported previously
by Zitzmann et al. (2010). Moreover, the reduction in the
viability of the NCI-H727 cells observed under treatment
with both mTOR inhibitors is not mirrored by a parallel
apoptosis induction (if not at the higher concentrations),
indicating that the antiproliferative effects of the
employed compounds are mediated by other mechanisms
in the ‘resistant’ cell line. Therefore, we examined the
effects of these compounds on cell-cycle progression, since
NVP-BEZ235 has been shown to induce G1 arrest (Maira
et al. 2008). Our data show that both NVP-BEZ235 and
everolimus induce an accumulation in the G0/G1 phase
of the cell cycle only in the ‘sensitive’ NCI-H720 cells. This
phenomenon is paralleled by a reduction in the levels of
phosphorylated GSK3b, which regulates cyclin D1 protein
levels, which are, in turn, downregulated. However, in the
NCI-H727 cells, the reduction in both phosphorylated
GSK3b and total cyclin D1 levels does not correspond to a
significant cell-cycle phase modification, suggesting that
further mechanisms allow ‘resistant’ BC cells to bypass
cyclin D1 downregulation and that the antiproliferative
effects of NVP-BEZ235 may be due to direct toxic effects
(necrosis). Further studies will clarify whether mTOR
resistance is due to altered cell-cycle progression.Figure 5
PI3K/AKT/mTOR pathway protein levels in BC cell lines and tissues. The
NCI-H720 and NCI-H727 cells were incubated for 72 h in a culture medium
supplemented with 100 nM NVP-BEZ 235 or everolimus, and control cells
were treated with a vehicle solution. (A) Total proteins were isolated from
the NCI-H727 and NCI-H720 cells and western blot analysis for total mTOR,
phosphorylated mTOR (p-mTOR), total AKT, and phosphorylated AKT
(p-AKT) expression was performed. b-Actin is shown as a loading control.
Lane 1, mock-treated cells. Lane 2, cells treated with NVP-BEZ235. Lane 3,
cells treated with everolimus. (B) The NCI-H720 (black bars) and NCI-H727
(white bars) cells were lysed and processed for total and phosphorylated
p70S6K (p-p70S6K) SureFire assays in duplicate in three independent
experiments. p-p70S6K levels were calculated as the ratio of p-p70S6K:total
p70S6K cps output for each sample. Data are expressed as percentage of
p-p70S6K vs the control, considering as the control sample the untreated
NCI-H720 cells. **P!0.01 vs the untreated control cells. #P!0.01 vs the
control NCI-H720 cells. (C) The NCI-H720 (black bars) and NCI-H727 (white
bars) cells were lysed and processed for total and phosphorylated ERK1/2
(p-ERK1/2) SureFire assays in duplicate in three independent experiments.
p-ERK1/2 levels were calculated as the ratio of p-ERK1/2:total ERK1/2 cps
output for each sample. Data are expressed as percentage of p-ERK1/2 vs
the control, considering as the control sample the untreated NCI-H720 cells.
**P!0.01 vs the untreated control cells. #P!0.01 vs the control NCI-H720
cells. (D) Five ‘sensitive’ (black bars) and five ‘resistant’ (white bars) BC
human tissues were disrupted, lysed, and processed for western blot
analysis for p-mTOR, total mTOR, p-p70S6K, total p70S6K (p70S6K), p-AKT,
total AKT, p-ERK1/2, ERK1/2, and b-actin expression for normalization
purposes. Protein levels were measured as the ratio of the protein optical
density (OD) to the b-actin OD of the same sample, and they are expressed
as arbitrary units (meanGS.E.M.).
Published by Bioscientifica Ltd.
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mTOR inhibitor NVP-BEZ235 is twofold more effective
than everolimus in ‘sensitive’ human BC tissues and cell
lines but not in ‘resistant’ ones. Therefore, we set out to
identify possible markers of sensitivity to mTOR inhibitors
that may enable the selection of the correct drug for BCs.
In our settings, ‘sensitive’ BC primary cultures were
derived from significantly younger patients when
compared with those bearing ‘resistant’ BCs. Clinical
studies evaluating the efficacy of everolimus in NETs
have reported that the overall survival is greater in patients
in the treatment arm than in those in the placebo arm
independent of age (Pavel et al. 2011, Yao et al. 2011),
even in the settings of BCs (Fazio et al. 2013). However,
these studies did not examine the relationship between
age and the efficacy of mTOR inhibitors in terms of tumor
bulk reduction. Further analyses of the data collected
during these interventional studies are necessary to clarify
whether age may be considered a prognostic index of
sensitivity to mTOR inhibitor therapy.
In addition, the expression level of mTOR pathway
components was evaluated in the NCI-H720 and NCI-
H727 cells. As has been reported already, the ‘sensitive’ BC
cell line showed higher total and phosphorylated mTOR
levels than the ‘resistant’ BC cells, in keeping with the
higher sensitivity of these cells to mTOR inhibitors. In
addition, our data show that in both ‘sensitive’ and
‘resistant’ BC cells, everolimus is more effective than
NVP-BEZ235 in reducing mTOR phosphorylation, in
keeping with the reported lower IC50 of the first
compound (1.6–2.4 nM) when compared with the second
compound (6.5–21 nM) (Sedrani et al. 1998, Liu et al.
2009). Therefore, the reduction in mTOR phosphorylation
shall not be considered as a marker of sensitivity to the
antiproliferative effects of mTOR inhibitors.
Similarly to total mTOR levels, basal AKT protein
levels were also higher in the ‘sensitive’ BC cell line, where
phosphorylated AKT levels were reduced only by NVP-
BEZ235. This evidence is in agreement with the ‘rebound’
hypothesis, which might explain the resistance of mTOR
inhibitors. However, in the ‘resistant’ BC cell line,
phosphorylated AKT levels were not modified by
either mTOR inhibitor, in keeping with previous results
(Zitzmann et al. 2010), indicating that the ‘rebound’
hypothesis might not hold true in ‘resistant’ BC cells. In
addition, p70S6K phosphorylation was strongly reduced
by mTOR inhibitors in the ‘sensitive’ BC cells, while the
‘resistant’ BC cells displayed much lower basal p70S6K
phosphorylation levels, which were not modified by the
employed drugs, despite the reduction in phosphorylatedhttp://erc.endocrinology-journals.org q 2013 Society for Endocrinology
DOI: 10.1530/ERC-13-0042 Printed in Great BritainmTOR levels. The latter evidence may indicate that in the
‘resistant’ BC cells mTOR inhibition is not mirrored by a
downstream downregulation and that p70S6K may be the
key for mTOR resistance in human BCs. Therefore, these
data suggest that the ‘resistant’ phenotype in BCs is
correlated with a decreased signaling efficiency of the
AKT/mTOR/p70S6K pathway. In addition, basal AKT and
p70S6K levels may differentiate between BCs that are likely
to respond to mTOR inhibitors and those that are not
likely to respond. Moreover, the evidence that ERK1/2
phosphorylation is not affected by either mTOR inhibitor
in the ‘resistant’ BC cells supports the hypothesis that
drugs inhibiting PI3K may not be useful to overcome the
resistance to mTOR inhibitors in BCs. Our data indeed
show that the ERK1/2 pathway, which is triggered by PI3K,
is not affected by either mTOR inhibitor in ‘resistant’ BC
cells. On the other hand, ERK1/2 protein levels are higher
in the ‘sensitive’ BC cells than in the ‘resistant’ BC cells,
possibly indicating that this pathway is important in
regulating the growth of ‘sensitive’ BC cells and may
represent a putative sensitivity marker.
The hypothesis that the identified proteins may be
considered as putative markers of sensitivity to mTOR
inhibitors is further strengthened by the evidence that
the same proteins have been found to be overexpressed
in an independent group of human BCs, whose sensi-
tivity to mTOR inhibitors had been tested previously.
Our data indeed show that higher basal mTOR, p70S6K,
AKT, and ERK1/2 protein levels characterize BC tissues
that respond to everolimus in terms of cell viability
reduction in vitro.
In conclusion, our data indicate that, among the
signaling molecules participating in the AKT/mTOR
pathway, basal mTOR, p70S6K, AKT, and ERK1/2 proteins
may be useful markers to identify human BCs that may
benefit from medical therapy with mTOR inhibitors. The
suitability of such candidate markers, however, needs to
be confirmed in clinical trials. Our results provide the
scientific grounds on which in vivo studies could be
designed in the near future.Declaration of interest
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